We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Presence of Estrogen Metabolites in Urine Predicts Cancer

By Labmedica staff writers
Posted on 14 Feb 2008
Estrogens can initiate cancer when natural mechanisms of protection do not work properly in the body, allowing estrogen metabolites to react with DNA. More...
A simple test can determine the presence of the estrogen metabolites in urine and be an indication of breast and prostate cancer risk.

Estrogen metabolites react predominantly with the first two DNA bases, adenine and guanine, to form estrogen-DNA adducts. The resulting damage generated by the reaction can give rise to mutations that eventually initiate cancer. The important estrogen-DNA adducts spontaneously fall out of the DNA, leaving behind gaps that generate cancer-initiating mutations. The estrogen-DNA adducts eventually make their way out of cells and are excreted in urine.

The screening test developed by scientists analyzes estrogen metabolite profiles in humans and simultaneously associate the profile with risk of getting breast cancer. A one-ounce sample of urine is tested using tandem mass spectrometry, which analyzes about 40 estrogen-related compounds, including estrogen-DNA adducts.

Scientists analyzed estrogen-DNA from 46 women with normal risk for breast cancer, 12 women at high risk of developing breast cancer, and 17 women diagnosed with breast cancer. They found women at high risk of breast cancer and the women with breast cancer had significantly higher levels of the estrogen-DNA adducts in their urine samples, while the women with normal risk for breast cancer had low levels.

The University of Nebraska Medical Center (UNMC; Omaha, NE, USA) team stated that there is a single initiating step in cancer development and that cancer can be assessed, prevented, and detected by understanding this common mechanism.

Eleanor Rogan, Ph.D., who took part in the study, said, "We have found the first step that starts a cell down the road to becoming a cancer cell. By preventing this first step from happening, we think we can stop the development of breast or prostate cancer. The combination of an early detection test for cancer risk with administration of preventing agents should enable us to significantly reduce the number of women and men that develop breast or prostate cancer.”

"If these protections are insufficient, due to genetic, lifestyle, or environmental influences, we think cancer can result,” Dr. Cavalieri said. "Now that we have the basic knowledge about this unifying mechanism of cancer initiation, we have a greater sense of urgency to assess people at risk, and at the same time, begin studies of prevention by using specific natural compounds.”

The findings were published in the December 2008 issue of the International Journal of Cancer. The study involved investigators at the University of Nebraska Medical Center (Omaha, NE, USA), Mayo Clinic (Scottsdale, AZ, USA), and the Italian National Cancer Institute (Naples, Italy).


Related Links:
University of Nebraska Medical Center
Mayo Clinic

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.